A Pharmacokinetic and Clotting Activity Study of FVIII-PEGLip Administered Intravenously to Severe Haemophilia A Patients With and Without Inhibitors to FVIII
The purpose of this study is to demonstrate that PEGylated liposomes (PEGLip) can shield FVIII from the immune system and inhibitors, and therefore provide a prophylactic FVIII replacement therapy for patients with inhibitors to FVIII.
100 Clinical Results associated with Ascension Healthcare Development Ltd.
0 Patents (Medical) associated with Ascension Healthcare Development Ltd.
100 Deals associated with Ascension Healthcare Development Ltd.
100 Translational Medicine associated with Ascension Healthcare Development Ltd.